Mineralys Therapeutics (MLYS) Financials

$16.10 +0.78 (+5.09%)

As of 04:00 PM Eastern

Annual Income Statements for Mineralys Therapeutics

This table shows Mineralys Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-178	-72	-30
Consolidated Net Income / (Loss)	-178	-72	-30
Net Income / (Loss) Continuing Operations	-178	-72	-30
Total Pre-Tax Income	-178	-72	-30
Total Operating Income	-192	-85	-31
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	192	85	31
Selling, General & Admin Expense	24	14	5.23
Research & Development Expense	169	70	26
Total Other Income / (Expense), net	15	13	1.68
Interest & Investment Income	15	13	1.68
Other Income / (Expense), net	0.01	-	0.00
Basic Earnings per Share	($3.66)	($1.99)	($5.77)
Weighted Average Basic Shares Outstanding	48.54M	36.19M	5.17M
Diluted Earnings per Share	($3.66)	($1.99)	($5.77)
Weighted Average Diluted Shares Outstanding	48.54M	36.19M	5.17M
Weighted Average Basic & Diluted Shares Outstanding	49.84M	49.63M	-

This table shows Mineralys Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-49	-56	-41	-32	-24	-23	-12	-13	-	-6.68
Consolidated Net Income / (Loss)	-49	-56	-41	-32	-24	-23	-12	-13	-	-6.68
Net Income / (Loss) Continuing Operations	-49	-56	-41	-32	-24	-23	-12	-13	-	-6.68
Total Pre-Tax Income	-49	-56	-41	-32	-24	-23	-12	-13	-	-6.68
Total Operating Income	-52	-60	-45	-35	-28	-26	-16	-15	-	-7.42
Total Operating Expenses	52	60	45	35	28	26	16	15	-	7.42
Selling, General & Admin Expense	7.20	6.12	5.90	4.61	4.03	3.77	3.85	2.65	-	1.36
Research & Development Expense	45	54	39	31	24	22	12	12	-	6.06
Total Other Income / (Expense), net	2.82	3.76	4.15	3.85	3.32	3.51	3.59	2.33	-	0.75
Interest & Investment Income	2.81	3.77	4.15	3.85	3.32	3.51	3.59	2.33	-	0.74
Other Income / (Expense), net	0.01	-0.01	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	($1.00)	($1.13)	($0.83)	($0.70)	($0.60)	($0.57)	($0.31)	($0.51)	-	($1.29)
Weighted Average Basic Shares Outstanding	48.54M	49.82M	49.36M	44.90M	36.19M	39.93M	39.75M	24.76M	5.17M	5.18M
Diluted Earnings per Share	($1.00)	($1.13)	($0.83)	($0.70)	($0.60)	($0.57)	($0.31)	($0.51)	-	($1.29)
Weighted Average Diluted Shares Outstanding	48.54M	49.82M	49.36M	44.90M	36.19M	39.93M	39.75M	24.76M	5.17M	5.18M
Weighted Average Basic & Diluted Shares Outstanding	49.84M	49.77M	49.73M	49.65M	49.63M	41.11M	-	-	0.00	-

This table details how cash moves in and out of Mineralys Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	65	-38	77
Net Cash From Operating Activities	-166	-81	-29
Net Cash From Continuing Operating Activities	-166	-81	-29
Net Income / (Loss) Continuing Operations	-178	-72	-30
Consolidated Net Income / (Loss)	-178	-72	-30
Depreciation Expense	0.04	0.00	-
Amortization Expense	-9.41	-6.87	-0.65
Non-Cash Adjustments To Reconcile Net Income	11	5.06	0.46
Changes in Operating Assets and Liabilities, net	9.52	-7.47	0.77
Net Cash From Investing Activities	115	-160	-22
Net Cash From Continuing Investing Activities	115	-160	-22
Purchase of Property, Plant & Equipment	-0.10	0.00	-
Purchase of Investments	-373	-348	-72
Sale and/or Maturity of Investments	489	188	50
Net Cash From Financing Activities	116	203	128
Net Cash From Continuing Financing Activities	116	203	128
Repurchase of Common Equity	-0.44	0.00	-
Issuance of Common Equity	116	203	-1.63
Other Financing Activities, net	0.30	0.19	0.00

This table details how cash moves in and out of Mineralys Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	17	29	-23	41	-37	-15	-37	51	39	-
Net Cash From Operating Activities	-67	-50	-30	-19	-29	-19	-20	-13	-10	-
Net Cash From Continuing Operating Activities	-67	-50	-30	-19	-29	-19	-20	-13	-10	-
Net Income / (Loss) Continuing Operations	-49	-56	-41	-32	-24	-23	-12	-13	-9.07	-
Consolidated Net Income / (Loss)	-49	-56	-41	-32	-24	-23	-12	-13	-9.07	-
Depreciation Expense	0.02	0.01	0.01	0.01	-	-	-	0.00	-	-
Amortization Expense	-1.34	-2.71	-2.85	-2.51	-2.07	-1.96	-1.98	-0.86	-0.41	-
Non-Cash Adjustments To Reconcile Net Income	3.13	3.14	2.87	2.19	1.46	1.58	1.28	0.75	0.22	-
Changes in Operating Assets and Liabilities, net	-20	5.72	11	13	-3.98	4.11	-7.54	-0.06	-0.92	-
Net Cash From Investing Activities	84	80	7.74	-56	-8.09	4.01	-16	-140	50	-
Net Cash From Continuing Investing Activities	84	80	7.74	-56	-8.09	4.01	-16	-140	50	-
Purchase of Investments	-64	-59	-127	-123	-73	-56	-56	-163	-	-
Sale and/or Maturity of Investments	148	139	135	68	65	60	40	23	50	-
Net Cash From Financing Activities	0.09	-0.00	-0.15	116	0.07	0.18	-0.58	204	-1.07	-
Net Cash From Continuing Financing Activities	0.09	-0.00	-0.15	116	0.07	0.18	-0.58	204	-1.07	-
Repurchase of Common Equity	-0.05	-0.04	-0.28	-0.06	-	-	-	0.00	-	-
Issuance of Common Equity	0.08	-	0.08	116	0.06	-	-0.58	204	-1.07	-
Other Financing Activities, net	0.05	0.04	0.05	0.15	0.01	0.18	-	0.00	-	-

This table presents Mineralys Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	206	252	114
Total Current Assets	205	249	113
Cash & Equivalents	114	49	88
Short-Term Investments	84	187	22
Prepaid Expenses	7.16	13	2.70
Plant, Property, & Equipment, net	0.05	0.00	0.00
Total Noncurrent Assets	0.50	2.53	1.63
Long-Term Investments	0.00	2.48	0.00
Other Noncurrent Operating Assets	0.50	0.05	1.63
Total Liabilities & Shareholders' Equity	206	252	114
Total Liabilities	15	10	8.07
Total Current Liabilities	15	10	8.07
Accounts Payable	0.48	0.60	1.91
Accrued Expenses	14	9.88	6.16
Total Noncurrent Liabilities	0.00	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	191	241	-52
Total Preferred & Common Equity	191	241	-52
Total Common Equity	191	241	-52
Common Stock	494	366	0.54
Retained Earnings	-303	-125	-53

This table presents Mineralys Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023
Total Assets	268	318	347	278
Total Current Assets	268	318	347	265
Cash & Equivalents	97	68	90	86
Short-Term Investments	166	243	248	167
Prepaid Expenses	4.13	6.89	8.25	12
Plant, Property, & Equipment, net	0.07	0.04	0.05	0.00
Total Noncurrent Assets	0.45	0.45	0.38	12
Long-Term Investments	0.00	0.00	0.00	12
Other Noncurrent Operating Assets	0.45	0.45	0.38	0.05
Total Liabilities & Shareholders' Equity	268	318	347	278
Total Liabilities	31	28	19	14
Total Current Liabilities	31	28	19	14
Accounts Payable	3.11	1.71	4.26	5.57
Accrued Expenses	28	27	15	7.97
Total Noncurrent Liabilities	0.00	0.00	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	237	290	328	264
Total Preferred & Common Equity	237	290	328	264
Total Common Equity	237	290	328	264
Common Stock	491	487	484	364
Retained Earnings	-254	-197	-156	-100

This table displays calculated financial ratios and metrics derived from Mineralys Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-120.45%	-184.90%	0.00%
EBIT Growth	-127.27%	-168.97%	0.00%
NOPAT Growth	-127.27%	-168.93%	0.00%
Net Income Growth	-147.31%	-141.28%	0.00%
EPS Growth	-83.92%	65.51%	0.00%
Operating Cash Flow Growth	-104.89%	-177.79%	0.00%
Free Cash Flow Firm Growth	-93.01%	0.00%	0.00%
Invested Capital Growth	-429.22%	156.36%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-13.04%	-1,657.00%	0.00%
EBIT Q/Q Growth	-14.28%	0.00%	0.00%
NOPAT Q/Q Growth	-14.29%	0.00%	0.00%
Net Income Q/Q Growth	-16.02%	0.00%	0.00%
EPS Q/Q Growth	-12.27%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-29.48%	-30.13%	0.00%
Free Cash Flow Firm Q/Q Growth	-35.03%	0.00%	0.00%
Invested Capital Q/Q Growth	74.02%	212.09%	0.00%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	92.42%	84.93%	94.68%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-82.24%	-41.38%	-28.01%
Cash Return on Invested Capital (CROIC)	0.00%	-3,092.63%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-82.24%	-22.49%	13.76%
Return on Equity Simple (ROE_SIMPLE)	-92.97%	-29.81%	57.01%
Net Operating Profit after Tax (NOPAT)	-135	-59	-22
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-19.73%	-7.24%	-7.05%
Return On Investment Capital (ROIC_SIMPLE)	-70.42%	-24.57%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-192	-85	-31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-202	-92	-32
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.20	1.47	0.00
Price to Tangible Book Value (P/TBV)	3.20	1.47	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	54.37	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.01	-1.00	-1.04
Leverage Ratio	1.06	1.05	1.08
Compound Leverage Factor	0.98	0.89	1.02
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	149.14%
Common Equity to Total Capital	100.00%	100.00%	-49.14%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	21.07	19.57	13.83
Noncontrolling Interest Sharing Ratio	0.00%	45.65%	149.14%
Liquidity Ratios	-	-	-
Current Ratio	14.02	23.76	13.98
Quick Ratio	13.53	22.57	13.65
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-126	-65	0.00
Operating Cash Flow to CapEx	-173,243.75%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-6.93	2.11	-3.74
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-9.04	5.84	0.00
Enterprise Value (EV)	414	114	241
Market Capitalization	613	354	192
Book Value per Share	$3.84	$5.87	($10.12)
Tangible Book Value per Share	$3.84	$5.87	($10.12)
Total Capital	191	241	106
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-198	-239	-110
Capital Expenditures (CapEx)	0.10	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.48	2.05	-5.37
Debt-free Net Working Capital (DFNWC)	191	239	105
Net Working Capital (NWC)	191	239	105
Net Nonoperating Expense (NNE)	43	13	7.76
Net Nonoperating Obligations (NNO)	-198	-239	-110
Total Depreciation and Amortization (D&A)	-9.36	-6.87	-0.65
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.66)	($1.99)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	48.54M	36.19M	0.00
Adjusted Diluted Earnings per Share	($3.66)	($1.99)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	48.54M	36.19M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.84M	49.63M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-135	-59	-22
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.24%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Mineralys Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-78.25%	-122.48%	-170.96%	-139.75%	-7,162.68%	-280.58%	0.00%	0.00%	0.00%	0.00%
EBIT Growth	-86.77%	-128.81%	-187.06%	-136.73%	0.00%	-254.13%	0.00%	0.00%	0.00%	0.00%
NOPAT Growth	-86.81%	-128.77%	-187.05%	-136.73%	0.00%	-253.94%	0.00%	0.00%	0.00%	0.00%
Net Income Growth	-100.69%	-147.55%	-237.81%	-149.90%	0.00%	-240.82%	0.00%	0.00%	0.00%	0.00%
EPS Growth	-66.67%	-98.25%	-167.74%	-37.25%	0.00%	55.81%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-130.64%	-163.71%	-47.88%	-49.82%	-184.52%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Growth	-7.78%	-4.65%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	-429.22%	-1,320.18%	0.00%	0.00%	156.36%	0.00%	0.00%	0.00%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	15.51%	-30.86%	-26.79%	-27.16%	-5.46%	-59.38%	-12.18%	-3,751.71%	94.47%	0.00%
EBIT Q/Q Growth	13.91%	-33.10%	-27.73%	-27.61%	-5.47%	-66.98%	-5.34%	0.00%	100.00%	0.00%
NOPAT Q/Q Growth	13.87%	-33.07%	-27.73%	-27.61%	-5.47%	-66.97%	-5.34%	0.00%	100.00%	0.00%
Net Income Q/Q Growth	13.13%	-37.37%	-30.17%	-29.19%	-7.16%	-87.46%	3.70%	0.00%	0.00%	0.00%
EPS Q/Q Growth	11.50%	-36.14%	-18.57%	-16.67%	-5.26%	-83.87%	39.22%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-33.19%	-66.48%	-57.51%	33.96%	-52.28%	6.65%	-59.58%	-25.42%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-57.41%	-63.07%	25.54%	43.60%	-52.83%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	74.02%	-26.88%	-99.81%	-599.76%	212.09%	0.00%	0.00%	100.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%
Interest Burden Percent	94.57%	93.72%	90.81%	89.10%	88.01%	86.63%	77.16%	84.41%	0.00%	90.01%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-82.24%	-61.19%	-82.50%	-55.36%	-41.38%	0.00%	0.00%	0.00%	-28.01%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-3,092.63%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-82.24%	-61.19%	-82.50%	-55.36%	-22.49%	0.00%	0.00%	0.00%	13.76%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-64.68%	-41.25%	-27.68%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-36	-42	-32	-25	-19	-18	-11	-10	0.00	-5.20
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-5.81%	-5.39%	-6.04%	-3.99%	-2.86%	-3.29%	0.00%	0.00%	0.00%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-18.95%	-	-	-	-8.04%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-52	-60	-45	-35	-28	-26	-16	-15	0.00	-7.42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-53	-63	-48	-38	-30	-28	-18	-16	-0.41	-7.42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.20	2.54	2.00	1.95	1.47	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	3.20	2.54	2.00	1.95	1.47	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	54.37	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-1.06	-1.07	-1.03	-1.00	-1.01	0.00	0.00	-1.04	0.00
Leverage Ratio	1.06	1.09	1.10	1.06	1.05	1.05	0.00	0.00	1.08	0.00
Compound Leverage Factor	1.00	1.02	1.00	0.94	0.93	0.91	0.00	0.00	0.00	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	149.14%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	-49.14%	0.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	23.32	10.53	12.03	20.19	20.32	0.00	0.00	0.00	14.73	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	45.65%	0.00%	0.00%	0.00%	149.14%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	14.02	8.55	11.20	18.06	23.76	19.60	0.00	0.00	13.98	0.00
Quick Ratio	13.53	8.42	10.96	17.63	22.57	18.74	0.00	0.00	13.65	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27	-17	-11	-14	-25	-17	0.00	0.00	0.00	0.00
Operating Cash Flow to CapEx	0.00%	-135,637.84%	0.00%	-32,438.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-6.93	-27	-21	-11	2.11	-1.88	0.00	0.00	-3.74	0.00
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-9.04	-25	-21	-11	5.84	-1.88	0.00	0.00	0.00	0.00
Enterprise Value (EV)	414	339	270	302	114	0.00	0.00	188	241	0.00
Market Capitalization	613	602	581	641	354	0.00	0.00	188	192	192
Book Value per Share	$3.84	$4.76	$5.84	$6.61	$5.87	$6.61	$0.00	$0.00	($10.12)	$0.00
Tangible Book Value per Share	$3.84	$4.76	$5.84	$6.61	$5.87	$6.61	$0.00	$0.00	($10.12)	$0.00
Total Capital	191	237	290	328	241	264	0.00	0.00	106	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-198	-264	-311	-339	-239	-266	0.00	0.00	-110	0.00
Capital Expenditures (CapEx)	0.00	0.04	0.00	0.06	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.48	-27	-22	-11	2.05	-1.93	0.00	0.00	-5.37	0.00
Debt-free Net Working Capital (DFNWC)	191	236	290	328	239	252	0.00	0.00	105	0.00
Net Working Capital (NWC)	191	236	290	328	239	252	0.00	0.00	105	0.00
Net Nonoperating Expense (NNE)	13	14	9.40	6.75	4.99	4.37	1.13	2.15	0.00	1.48
Net Nonoperating Obligations (NNO)	-198	-264	-311	-339	-239	-266	0.00	0.00	-110	0.00
Total Depreciation and Amortization (D&A)	-1.32	-2.70	-2.84	-2.50	-2.07	-1.96	-1.98	-0.86	-0.41	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.00)	($1.13)	($0.83)	($0.70)	($0.60)	($0.57)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	48.54M	49.82M	49.36M	44.90M	36.19M	39.93M	0.00	0.00	5.17M	0.00
Adjusted Diluted Earnings per Share	($1.00)	($1.13)	($0.83)	($0.70)	($0.60)	($0.57)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	48.54M	49.82M	49.36M	44.90M	36.19M	39.93M	0.00	0.00	5.17M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.84M	49.77M	49.73M	49.65M	49.63M	41.11M	0.00	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-36	-42	-32	-25	-19	-18	-11	-10	0.00	-5.20
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Mineralys Therapeutics' Financials

When does Mineralys Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Mineralys Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Mineralys Therapeutics' net income changed over the last 2 years?

Mineralys Therapeutics' net income appears to be on an upward trend, with a most recent value of -$177.81 million in 2024, rising from -$29.80 million in 2022. The previous period was -$71.90 million in 2023. View Mineralys Therapeutics' forecast to see where analysts expect Mineralys Therapeutics to go next.

What is Mineralys Therapeutics's operating income?

Mineralys Therapeutics's total operating income in 2024 was -$192.40 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $192.40 million

How has Mineralys Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Mineralys Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Mineralys Therapeutics have?

Mineralys Therapeutics' total liabilities were at $14.65 million at the end of 2024, a 39.7% increase from 2023, and a 81.6% increase since 2022.

How much cash does Mineralys Therapeutics have?

In the past 2 years, Mineralys Therapeutics' cash and equivalents has ranged from $49.30 million in 2023 to $114.09 million in 2024, and is currently $114.09 million as of their latest financial filing in 2024.

How has Mineralys Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Mineralys Therapeutics' book value per share changed from -10.12 in 2022 to 3.84 in 2024, a change of -138.0%.

Related Companies

This page (NASDAQ:MLYS) was last updated on 5/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Financials

Frequently Asked Questions About Mineralys Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Financials

Annual Income Statements for Mineralys Therapeutics

Quarterly Income Statements for Mineralys Therapeutics

Annual Cash Flow Statements for Mineralys Therapeutics

Quarterly Cash Flow Statements for Mineralys Therapeutics

Annual Balance Sheets for Mineralys Therapeutics

Quarterly Balance Sheets for Mineralys Therapeutics

Annual Metrics And Ratios for Mineralys Therapeutics

Quarterly Metrics And Ratios for Mineralys Therapeutics

Frequently Asked Questions About Mineralys Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools